We are a national leader in transplant with patient outcomes exceeding the national average across our heart, lung, kidney, pancreas and liver programs. We specialize in cancer-related transplantation, working as a unified team with our Comprehensive Cancer Center, which is among the elite one percent NCI-designated comprehensive cancer centers in the U.S.
One of a Few Hospitals in the Nation to Perform Dual Organ Transplants for Patients with Simultaneous Heart, Liver, Kidney or Lung Failure
One of the Longest-Running Adult & Pediatric Transplant Programs in the World
The Montefiore Einstein Center for Transplantation is an internationally recognized center for adult and pediatric transplantation in heart, lung, kidney, pancreas and liver with some of the highest survival rates in the U.S., including 100% survival of live liver donor transplant recipients and best risk-adjusted one-year survival heart transplant outcomes. Home to the first lung-liver transplant in New York State and one of the few hospitals in the nation to perform dual organ transplants for patients with simultaneous heart, liver, kidney or lung failure, we have one of the longest-running transplant programs in the world.
We performed one of the world’s first pediatric kidney transplants, established one of the nation’s first pediatric transplant program and dialysis centers, as well as one of the longest NIH-funded liver research centers. We performed the first transplantation of a viral hepatitis-infected liver into an uninfected recipient treated with antiviral therapy post-transplant. As a global leader in the most complex transplantation cases, we performed the world’s first HIV-positive to HIV-positive heart transplant and are one of the few centers in the nation and the only destination in New York that performs bloodless heart transplantation.
100% Survival of Pediatric & Adult Live Donor Liver Transplant Recipients
Center for Transplantation Highlights
Leaders in the Science of Transplantation
We have been leading the way with groundbreaking research for over six decades and continue advancing the field through discovery and innovation. Our researchers have made substantial contributions, including transplantation for highly immune-sensitized patients, understanding the mechanisms of organ rejection, and ways to perform transplants in people with viral hepatitis and HIV. We are also using stem-cell therapy to “grow” new tissues and organs and are one of the few centers in the world researching stem cell therapy for regenerating heart muscle, particularly for left ventricular assist device (LVAD) recipients.
State-of-the-Art Techniques & Technology
We utilize the latest diagnostics and therapeutic techniques and technologies for the most complex transplantations and life-threatening organ failure. Our world-renowned transplant surgeons use the latest minimally-invasive and robotically-assisted surgical approaches for faster recovery. We are leaders in the science of living donor transplantation, with state-of-the-art desensitization programs and an advanced immunology laboratory for patients with circulating antibodies and incompatible blood type (ABO-incompatible).
We were the first in the Northeast to eliminate the need for liver transplantation through the use of MARS liver dialysis technology. We also performed the first transplantation of a viral hepatitis-infected liver into an uninfected recipient treated with antiviral therapy post-transplant, and the world’s first HIV-positive to HIV-positive heart transplant, innovations that expand the pool of donors so that more people will have quicker access to a lifesaving organ.
We Performed the World’s First HIV-Positive to HIV-Positive Heart Transplant
Líder nacional en trasplantes de órganos vivos.
Nuestro sólido programa de donantes en vida ofrece una manera para que las personas reciban un trasplante que les salve la vida sin tener que esperar tanto. En el programa participan familiares, amigos y donantes vivos anónimos, lo que reduce el tiempo de espera para el trasplante en receptores compatibles. Se ha demostrado que las tasas de éxito de los trasplantes de donantes en vida son equivalentes a las tasas de éxito de los trasplantes de donantes fallecidos. En Montefiore Einstein, estamos entre los mejores del país con tasas de supervivencia de trasplante de hígado a tres años del 100 % para receptores pediátricos y adultos de trasplantes de hígado de donantes en vida.
Para nuestros pacientes que necesitan un trasplante de riñón o hígado, creamos la revolucionaria herramienta digital «Quiero Vivir», pionera en su tipo, que utiliza inteligencia artificial (IA) y video para contar su historia y explicar por qué desean vivir. Esta herramienta exclusiva ofrece un enfoque totalmente novedoso y único para ayudar a quienes necesitan un trasplante a superar la dificultad de pedir ayuda y contactar con posibles donantes.
Living Donor Circle of Excellence Member
Montefiore Einstein is proud to be a member of the American Society of Transplantation's Living Donor Circle of Excellence program. The program recognizes companies that have policies in place to support living donor employees who donate a kidney or a part of their liver.
Living Donor Transplant Survival Rates Among the Highest in the Nation
Some of Our Stories of Lives Saved
-
Adriana y Nicole
Four days into her life, little Adriana became very ill. It was, among other things, her liver. Her desperate mother posted a plea on social media, asking for a living organ donor. Maybe someone out there would respond.
-
Paul y Jeremy
La sangre se acumulaba en las venas de Paul y, si alguna de ellas se hubiera reventado, podría haber sufrido una hemorragia potencialmente mortal. Al enfrentarse al peligro, encontró el humor.
-
Rebecca y Chris
Tras servir en Irak y Afganistán, el veterano del ejército Chris Forthman había visto tanta maldad en el mundo. No es de extrañar que el mayor acto de bondad comenzara con él.
Center for Transplantation Highlights
-
100%
three-year survival of pediatric and adult recipients of live donor liver transplants
-
#1
in U.S. risk-adjusted one-year survival heart transplant outcomes
-
100%
one-year survival of adult Liver-Heart and pediatric Kidney-Liver transplant recipients
-
#1
in U.S. 3-year adult kidney transplant outcomes
